Enovis (Enovis) Cash And Cash Equivalents

: $36 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

Enovis's quarterly cash and cash equivalents declined from Jun. 2023 ($32.49 Mil) to Sep. 2023 ($32.13 Mil) but then increased from Sep. 2023 ($32.13 Mil) to Dec. 2023 ($36.19 Mil).

Enovis's annual cash and cash equivalents declined from Dec. 2021 ($680.25 Mil) to Dec. 2022 ($24.30 Mil) but then increased from Dec. 2022 ($24.30 Mil) to Dec. 2023 ($36.19 Mil).

Enovis Cash And Cash Equivalents Historical Data

The historical data trend for Enovis's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

109.63

97.07

680.25

24.30

36.19

Enovis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															24.30	21.90	32.49	32.13	36.19

Enovis Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Enovis (NYSE:ENOV) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Enovis Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Enovis's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Enovis (Enovis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (NYSE:ENOV) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

C520:Germany

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.

Executives

John Kleckner	officer: Principal Accounting Officer	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben)	officer: SVP, Chief Financial Officer	2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota	director	8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall	director
Brady Shirley	officer: EVP, Colfax, Pres. & CEO, DJO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang	officer: SVP, Chief HR Officer	C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy	officer: SVP, General Counsel	P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor	officer: SVP??Strategy & Business Deve.	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola	director, officer: President & CEO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix	officer: SVP, Chief Financial Officer	2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz	director	1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor	director	3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda	officer: ESAB President and SVP, Colfax	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts	officer: Controller, PAO	100 MATSONFORD ROAD, RADNOR PA 19087